The global polymyxins market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of multidrug-resistant bacteria and increasing number of hospital acquired infections. Polymyxins are broad spectrum antibiotics that are used for the treatment of various bacterial infections such as intestinal disease, infection, septicemia and peritonitis. The injection type segment accounted for the largest share in 2018 owing to its high efficacy against Gram-negative bacteria and low toxicity profile. Injection type segment is expected to maintain its dominance throughout the forecast period due to its high efficacy against Gram-negative bacteria and low toxicity profile.
Injection Type: The injection type segment accounted for the largest share in 2018 owing to its high efficacy against Gram-negative bacteria and low toxicity profile.
Intestinal Disease: Intestinal disease accounted for a significant share in 2018 owing mainly due increased incidence rates among children aged less than five years old as well as elderly people aged 65 years or more who have chronic diseases such as diabetes mellitus or chronic obstructive pulmonary disease (COPD). Intestinal disease is projected be one of fastest growing segments during 2020s with an estimated CAGR of 6%.
Some Of The Growth Factors Of This Market:
- Polymyxins are used to treat infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa and Acinetobacter baumannii.
- The emergence of multidrug-resistant Gram-negative bacteria is a major factor driving the growth of the polymyxins market.
- The increasing prevalence of chronic diseases such as diabetes and obesity is also expected to drive the growth of the polymyxins market in coming years, as these conditions increase susceptibility to infection and require treatment with antibiotics for longer periods than healthy individuals do.
- Increasing incidence rates of hospital acquired infections are also expected to drive the growth of this market in coming years, as they lead to increased use of antibiotics for treatment purposes.
- Increasing number of surgical procedures performed worldwide is also expected to drive this market in coming years.
Industry Growth Insights published a new data on “Polymyxins Market”. The research report is titled “Polymyxins Market research by Types (Injection Type, External), By Applications (Intestinal Disease, Infection, Septicemia, Peritonitis), By Players/Companies Meiji Seika Pharm, Shengxue Dacheng, Apeloa, Livzon Group, LKPC, Xellia, BIOK, Vetbiochem, Qianjiang Biochemical, VEGA, Huazhong Pharmaceutical”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Polymyxins Market Research Report
By Type
Injection Type, External
By Application
Intestinal Disease, Infection, Septicemia, Peritonitis
By Companies
Meiji Seika Pharm, Shengxue Dacheng, Apeloa, Livzon Group, LKPC, Xellia, BIOK, Vetbiochem, Qianjiang Biochemical, VEGA, Huazhong Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Polymyxins Market Report Segments:
The global Polymyxins market is segmented on the basis of:
Types
Injection Type, External
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Intestinal Disease, Infection, Septicemia, Peritonitis
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Meiji Seika Pharm
- Shengxue Dacheng
- Apeloa
- Livzon Group
- LKPC
- Xellia
- BIOK
- Vetbiochem
- Qianjiang Biochemical
- VEGA
- Huazhong Pharmaceutical
Highlights of The Polymyxins Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Injection Type
- External
- By Application:
- Intestinal Disease
- Infection
- Septicemia
- Peritonitis
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Polymyxins Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Polymyxins are a class of antibiotics that work by inhibiting the growth of bacteria. Polymyxins are most commonly used to treat infections caused by bacteria such as pneumonia, bronchitis, and urinary tract infections.
Some of the major companies in the polymyxins market are Meiji Seika Pharm, Shengxue Dacheng, Apeloa, Livzon Group, LKPC, Xellia, BIOK, Vetbiochem, Qianjiang Biochemical, VEGA, Huazhong Pharmaceutical.
The polymyxins market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Polymyxins Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Polymyxins Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Polymyxins Market - Supply Chain
4.5. Global Polymyxins Market Forecast
4.5.1. Polymyxins Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Polymyxins Market Size (000 Units) and Y-o-Y Growth
4.5.3. Polymyxins Market Absolute $ Opportunity
5. Global Polymyxins Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Polymyxins Market Size and Volume Forecast by Type
5.3.1. Injection Type
5.3.2. External
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Polymyxins Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Polymyxins Market Size and Volume Forecast by Application
6.3.1. Intestinal Disease
6.3.2. Infection
6.3.3. Septicemia
6.3.4. Peritonitis
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Polymyxins Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Polymyxins Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Polymyxins Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Polymyxins Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Polymyxins Demand Share Forecast, 2019-2026
9. North America Polymyxins Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Polymyxins Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Polymyxins Market Size and Volume Forecast by Application
9.4.1. Intestinal Disease
9.4.2. Infection
9.4.3. Septicemia
9.4.4. Peritonitis
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Polymyxins Market Size and Volume Forecast by Type
9.7.1. Injection Type
9.7.2. External
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Polymyxins Demand Share Forecast, 2019-2026
10. Latin America Polymyxins Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Polymyxins Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Polymyxins Market Size and Volume Forecast by Application
10.4.1. Intestinal Disease
10.4.2. Infection
10.4.3. Septicemia
10.4.4. Peritonitis
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Polymyxins Market Size and Volume Forecast by Type
10.7.1. Injection Type
10.7.2. External
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Polymyxins Demand Share Forecast, 2019-2026
11. Europe Polymyxins Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Polymyxins Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Polymyxins Market Size and Volume Forecast by Application
11.4.1. Intestinal Disease
11.4.2. Infection
11.4.3. Septicemia
11.4.4. Peritonitis
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Polymyxins Market Size and Volume Forecast by Type
11.7.1. Injection Type
11.7.2. External
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
1110.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Polymyxins Demand Share, 2019-2026
12. Asia Pacific Polymyxins Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Polymyxins Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Polymyxins Market Size and Volume Forecast by Application
12.4.1. Intestinal Disease
12.4.2. Infection
12.4.3. Septicemia
12.4.4. Peritonitis
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Polymyxins Market Size and Volume Forecast by Type
12.7.1. Injection Type
12.7.2. External
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Polymyxins Demand Share, 2019-2026
13. Middle East & Africa Polymyxins Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Polymyxins Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Polymyxins Market Size and Volume Forecast by Application
13.4.1. Intestinal Disease
13.4.2. Infection
13.4.3. Septicemia
13.4.4. Peritonitis
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Polymyxins Market Size and Volume Forecast by Type
13.7.1. Injection Type
13.7.2. External
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Polymyxins Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Polymyxins Market: Market Share Analysis
14.2. Polymyxins Distributors and Customers
14.3. Polymyxins Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Meiji Seika Pharm
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Shengxue Dacheng
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Apeloa
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Livzon Group
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. LKPC
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Xellia
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. BIOK
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Vetbiochem
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Qianjiang Biochemical
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. VEGA
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Huazhong Pharmaceutical
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
